Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heron Therapeutics, Inc. filings document financial results, governance matters, executive compensation arrangements, and capital-structure actions for a commercial-stage biotechnology company. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary revenue disclosures, business updates for the Acute Care franchise, and material corporate events.
Proxy and governance filings cover director elections, board committee matters, executive pay, equity-award disclosure, and stockholder voting. Other filings record amendments to employment and change-in-control provisions, board appointments, and stockholder approvals tied to potential common-stock issuance from convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
Heron Therapeutics, Inc. (HRTX) – Form 4 insider filing
EVP & Chief Development Officer William P. Forbes reported the vesting and automatic conversion of 3,874 restricted stock units (RSUs) into common shares on 07/19/2025 (transaction code “M”). No shares were sold, and the RSUs carried a $0.00 exercise price. Following the conversion, Forbes’ direct common-stock holdings increased to 138,940 shares. He still holds 38,743 unvested RSUs, which continue to vest quarterly through the original 01/19/2028 schedule. No other equity instruments or derivative transactions were disclosed.
- No cash proceeds were generated; the transaction simply moved shares from the derivative column to direct ownership.
- The filing does not indicate any open-market purchases or dispositions, suggesting the move is part of a pre-set equity-compensation plan.
Form 4 filing for Heron Therapeutics, Inc. (HRTX) discloses that Executive Vice President & Chief Financial Officer Ira Duarte converted 3,874 Restricted Stock Units (RSUs) into an equal number of common shares on 07/19/2025 (transaction code M).
Following the conversion, Duarte directly owns 152,523 HRTX common shares and retains 38,743 unvested RSUs. The RSUs originally granted on 01/19/2024 vest in 16 equal quarterly instalments; the reported tranche represents one of these scheduled releases. No shares were sold and no cash price is indicated (exercise price $0), so total insider ownership increased by the same amount as shares acquired.
No other non-derivative or derivative transactions were reported. This appears to be a routine vesting/settlement event rather than an open-market purchase or disposition.